The latest announcement is out from GeneDx Holdings ( (WGS) ).
On April 15, 2025, GeneDx Holdings Corp. announced an agreement to acquire Fabric Genomics for approximately $33 million, with potential additional payments based on future performance milestones. This acquisition aims to enhance GeneDx’s capabilities in decentralized genomic testing and AI-powered interpretation, expanding its market reach and improving the speed and accuracy of genetic disorder diagnoses. The merger is expected to close in the second quarter of 2025, subject to closing conditions, and will allow GeneDx to leverage Fabric Genomics’ AI platform to provide more scalable and impactful genomic interpretation services globally.
Spark’s Take on WGS Stock
According to Spark, TipRanks’ AI Analyst, WGS is a Neutral.
GeneDx Holdings has strong revenue growth and improving margins, but operational challenges remain due to persistent losses and negative cash flows. The stock is currently seeing positive momentum in the market, but its valuation is poor due to negative earnings. Strategic changes and strong guidance from the earnings call are positive, yet high denial rates and exiting a segment pose risks. Overall, the stock is moderately positioned with potential for future improvement.
To see Spark’s full report on WGS stock, click here.
More about GeneDx Holdings
GeneDx Holdings Corp. operates in the healthcare industry, focusing on genomic insights to improve health outcomes. The company is known for its rare disease data asset and exome and genome tests, which help translate complex genomic data into clinical answers, thereby enhancing personalized health plans and accelerating drug discovery.
YTD Price Performance: 28.37%
Average Trading Volume: 1,014,730
Technical Sentiment Signal: Sell
Current Market Cap: $2.84B
For an in-depth examination of WGS stock, go to TipRanks’ Stock Analysis page.